Related Experiment Videos
Molecular pathogenesis of meningiomas
Arie Perry1, David H Gutmann, Guido Reifenberger
1Division of Neuropathology, Washington University School of Medicine, St Louis, MO 63110-1093, USA. aperry@pathology.wustl.edu
Journal of Neuro-Oncology
|January 28, 2005
Summary
Meningiomas, common brain tumors, often arise from protein 4.1 superfamily gene inactivation. Understanding molecular changes in aggressive meningiomas may reveal new diagnostic markers and therapies.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Genetics
Background:
- Meningiomas are common central nervous system tumors originating from meningeal cells.
- While often benign (WHO grade I), rare variants and higher grades (WHO II-III) exhibit aggressive behavior and poor prognosis.
- Understanding meningioma pathology and molecular drivers is crucial for improved patient outcomes.
Purpose of the Study:
- To review key features of meningioma pathology.
- To provide an updated overview of molecular mechanisms in meningioma initiation and progression.
- To highlight potential for novel diagnostic and therapeutic strategies.
Main Methods:
- Literature review of meningioma pathology.
- Analysis of current research on molecular mechanisms of meningioma development.
- Summary of genetic alterations in different meningioma grades.
Main Results:
- Meningioma initiation is linked to inactivation of protein 4.1 superfamily members (e.g., merlin/schwannomin).
- Atypical meningiomas (WHO grade II) show complex genetic alterations including chromosomal losses and gains.
- Anaplastic meningiomas (WHO grade III) exhibit more intricate genetic changes, including alterations in CDKN2A/p14ARF/CDKN2B and 17q23 amplification.
Conclusions:
- Molecular insights into meningioma pathogenesis are advancing.
- Identification of genetic alterations may lead to novel diagnostic and prognostic markers.
- Understanding these mechanisms can facilitate the development of targeted therapeutic strategies.